Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Positronenemissionstomographie(PET)-geleitete Behandlung des Hodgkin-Lymphoms im frühen Stadium mit günstigen Risikofaktoren: Endresultate der internationalen randomisierten Phase-III-HD16-Studie der Deutschen Hodgkin-Studiengruppe

Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international randomized phase III HD16 trial conducted by the German Hodgkin Study Group

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Bröckelmann PJ, Angelopoulou MK, Vassilakopoulos TP (2016) Prognosticfactors in Hodgkin lymphoma. Semin Hematol 53:155–164

  2. 2.

    Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 68:116–132

  3. 3.

    Engert A, Raemaekers J (2016) Treatment of early-stage Hodgkin lymphoma. Semin Hematol 53:165–170

  4. 4.

    Franklin J, Eichenauer DA, Becker I et al (2017) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. Cochrane Database Syst Rev 13;9:CD8814

  5. 5.

    Bröckelmann PJ, Sasse S, Engert A (2018) Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 131:1666–1678

  6. 6.

    Straus DJ, Jung SH, Pitcher B et al (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013–1021

  7. 7.

    Fuchs M, Goergen H, Kobe C et al (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 37:2835–2845

  8. 8.

    Adams HJA, Kwee TC (2017) An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Semin Oncol 44:404–419

  9. 9.

    Hutchings M (2018) Improvements in imaging of Hodgkin lymphoma: positron emission tomography. Cancer J 24:215–222

  10. 10.

    Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607

  11. 11.

    Andre MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(10):1786–1794

  12. 12.

    Bröckelmann PJ, McMullen S, Wilson JB et al (2019) Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol 184:202–214

  13. 13.

    Lagerlöf I, Holte H, Glimelius I et al (2019) No excess long-term mortality in stage I–IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol. https://doi.org/10.1111/bjh.16232

  14. 14.

    Specht L (2018) Radiotherapy for Hodgkin lymphoma: reducing toxicity while maintaining efficacy. Cancer J 24:237–243

  15. 15.

    Edvardsson A, Kügele M, Alkner S et al (2019) Comparative treatment planning study for mediastinal Hodgkin’s lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy. Acta Oncol 58:95–104

Download references

Author information

Correspondence to Prof. Dr. med. Carsten Nieder.

Ethics declarations

Interessenkonflikt

C. Nieder gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Fuchs M, Goergen H, Kobe C et al (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 37:2835–2845

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nieder, C. Positronenemissionstomographie(PET)-geleitete Behandlung des Hodgkin-Lymphoms im frühen Stadium mit günstigen Risikofaktoren: Endresultate der internationalen randomisierten Phase-III-HD16-Studie der Deutschen Hodgkin-Studiengruppe. Strahlenther Onkol (2020). https://doi.org/10.1007/s00066-020-01593-0

Download citation